Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Net Cash Flow (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Net Cash Flow for 12 consecutive years, with -$14.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 480.09% year-over-year to -$14.9 million, compared with a TTM value of -$6.4 million through Sep 2025, down 143.58%, and an annual FY2024 reading of $21.0 million, up 111.89% over the prior year.
  • Net Cash Flow was -$14.9 million for Q3 2025 at CytomX Therapeutics, down from $1.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $137.8 million in Q1 2021 and bottomed at -$137.3 million in Q1 2023.
  • Average Net Cash Flow over 5 years is -$8.3 million, with a median of -$8.9 million recorded in 2023.
  • The sharpest move saw Net Cash Flow surged 498.98% in 2024, then plummeted 480.09% in 2025.
  • Year by year, Net Cash Flow stood at -$30.8 million in 2021, then skyrocketed by 420.66% to $98.6 million in 2022, then tumbled by 108.98% to -$8.9 million in 2023, then surged by 71.49% to -$2.5 million in 2024, then plummeted by 488.59% to -$14.9 million in 2025.
  • Business Quant data shows Net Cash Flow for CTMX at -$14.9 million in Q3 2025, $1.4 million in Q2 2025, and $9.6 million in Q1 2025.